您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > Ximelagatran
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Ximelagatran
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Ximelagatran图片
CAS NO:192939-46-1
包装与价格:
包装价格(元)
10mM (in 1mL DMSO)电议
500μg电议
1mg电议
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议

产品介绍
Ximelagatran (H 376/95) 是一种口服活性凝血酶抑制剂,可选择性和竞争性地抑制游离和凝块结合的凝血酶。Ximelagatran 还是一种抗凝药物,具有快速起效的抗凝作用,可预测的,剂量依赖性的药代动力学和药效学。
Cas No.192939-46-1
别名希美加群,H 376/95
Canonical SMILESO=C([C@@H]1CCN1C([C@@H](C2CCCCC2)NCC(OCC)=O)=O)NCC3=CC=C(C=C3)/C(N)=N/O
分子式C24H35N5O5
分子量473.57
溶解度DMSO: 250 mg/mL (527.91 mM); Methanol: 62.5 mg/mL (131.98 mM)
储存条件Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Ximelagatran (H 376/95) is an orally active thrombin inhibitor that selectively and competitively inhibits both free and clot-bound thrombin. Ximelagatran is an anticoagulant agent with a rapid onset of anticoagulant effect, predictable, dose-dependent pharmcokinetics and pharmacodynamics[1][2].

Ximelagatran is an orally administered direct thrombin inhibitor under development as an anticoagulant agent for prophylaxis against and treatment of thromboembolism. Ximelagatran is rapidly absorbed and quickly converted into its active form Melagatran, a reversible, active-site inhibitor of both free and clot-bound thrombin that has stable and reproducible pharmacokinetic properties. Initial studies have shown Ximelagatran to have good efficacy and safety in the prevention of venous thromboembolism after total knee or total hip replacement[3].

[1]. Colwell CW Jr, et al. Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study. J Thromb Haemost. 2003 Oct;1(10):2119-30. [2]. Gao JH, et al. Effects of different anticoagulant drugs on the prevention of complications in patients after arthroplasty: A network meta-analysis. Medicine (Baltimore). 2017 Oct;96(40):e8059. [3]. Francis CW, et al. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med. 2003 Oct 30;349(18):1703-12.